All peptides
Growth Hormone
Tesamorelin
GHRH analog studied for reducing visceral fat and supporting GH release.
Lyophilized vial
Tesamorelin is a growth-hormone-releasing hormone (GHRH) analog studied for its ability to stimulate the body’s own GH production. It is particularly researched for reducing visceral adipose tissue.
Research focus: Growth Hormone & Body Composition
Clinical research examines its effects on body composition, lipid profiles, and the pulsatile release of growth hormone, distinguishing it from direct GH administration.
Evidence grade
A
Half-life
Presentation
Lyophilized vial
What the research shows — and what it doesn’t
Evidence strength
Grade A: a randomised controlled trial of visceral fat reduction in HIV-associated lipodystrophy (PMID 25038357), pooled with a 2026 systematic review and meta-analysis of body-composition and safety outcomes (PMID 41545261). The evidence sits in that specific patient population, not in general body-composition use.
Safety context
What a grade does not mean
Safety
Related research
Related research is coming soon for this peptide.